Evidence map›Paper›PMID 35181583›Full record

ArticleCancer genomics & proteomics

Mapping Proteome Changes in Microsatellite Stable, Recurrent Colon Cancer Reveals a Significant Immune System Signature.

Magnus Berle, Kjersti E Hestetun, Heidrun Vethe, Simona Chera, Joao A Paulo, Olav Dahl, Mette Pernille Myklebust

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Magnus BerleDepartment of Clinical Medicine, University of Bergen, Bergen, Norway; magnus.berle@uib.no.
Kjersti E HestetunDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Heidrun VetheDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.
Simona CheraDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Joao A PauloDepartment of Cell Biology, Harvard Medical School, Boston, MA, U.S.A.
Olav DahlDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Mette Pernille MyklebustDepartment of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
University of Bergen · NOHaukeland University Hospital · NOUniversity Hospital of Geneva · CH

Funding

Advancing Multiplexed Isobaric Tag-based Strategies for Proteome ProfilingR01GM132129 · NIGMS · HARVARD MEDICAL SCHOOL · PI PAULO, JOAO A · 2019 to 2023
$1.7M
NIGMS NIH HHS R01 GM132129
6 · The paper itself

Abstract

BACKGROUND/

aimBetter stratification of the risk of relapse will help select the right patients for adjuvant treatment and improve targeted therapies for patients with colon cancer. MATERIALS AND

methodsTo understand why a subset of tumors relapse, we compared the proteome of two groups of patients with colon cancer with similar stage, stratified based on the presence or absence of recurrence.

resultsUsing tumor biopsies from the primary operation, we identified dissimilarity between recurrent and nonrecurrent mismatch satellite stable colon cancer and found that signaling related to immune activation and inflammation was associated with relapse.

conclusionImmune modulation may have an effect on mismatch satellite stable colon cancer. At present, immune therapy is offered primarily to microsatellite instable colon cancer. Hopefully, immune therapy in mismatch satellite stable colon cancer beyond PD-1 and PD-L1 inhibitors can be implemented.

Indexed as

Colonic NeoplasmsImmune SystemProteomeHumansMicrosatellite RepeatsNeoplasm Recurrence, LocalPrognosisProteomeColon cancerimmune systemmicrosatellite stableproteomicsrecurrence

Identifiers

PMID35181583
PMCPMC8865039
OpenAlexW4212807479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.